Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma somatostatin in advanced heart failure: association with cardiac filling pressures and outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A Novel SCN5A Variant Associated with Abnormal Repolarization, Atrial Fibrillation, and Reversible Cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Leucocyte Telomere Length and Risk of Cardiovascular Disease in a Cohort of 1,397 Danish Men and Women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Common genetic variants and risk of ischemic heart failure: an evaluation of a negative genetic study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Somatostatin inhibits intestinal motility and hormonal secretion and is a potent arterial vasoconstrictor of the splanchnic blood flow. It is unknown if somatostatin concentrations are associated with central hemodynamic measurements in patients with advanced heart failure (HF).

METHODS: A prospective study of HF patients with a left ventricular ejection fraction (LVEF) <45% referred to right heart catheterization (RHC) for evaluation for heart transplantation (HTX) or left ventricular assist device (LVAD).

RESULTS: Fifty-three patients were included with mean LVEF 18 ± 8% and majority in NYHA-class III-IV (79%). Median plasma somatostatin concentration was 18 pmol/L. In univariable regression analysis, log(somatostatin) was associated with increased central venous pressure (CVP; r2 = 0.14, p = 0.003) and a reduced cardiac index (CI; r2 = 0.15, p = 0.004). When adjusted for selected clinical variables (age, gender, LVEF, eGFR and BMI), log(somatostatin) remained a significant predictor of CVP (p = 0.044). Increased somatostatin concentrations predicted mortality in multivariable models (hazard ratio: 5.2 [1.2-22.2], p = 0.026) but not the combined endpoint of death, LVAD implantation or HTX.

CONCLUSIONS: Somatostatin concentrations were associated with CVP and CI in patients with HF. The pathophysiological mechanism may be related to congestion and/or hypoperfusion of the intestine. Somatostatin was an independent predictor of mortality in advanced HF.

OriginalsprogEngelsk
TidsskriftCardiology
Vol/bind145
Udgave nummer12
Sider (fra-til)769-778
Antal sider10
ISSN0008-6312
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

© 2020 S. Karger AG, Basel.

ID: 61389471